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Abstract: In this work we used a combination of different techniques to investigate the adsorption properties 
of curcumin by zeolite type A for potential use as an anticancer drug carrier. Curcumin is a natural water-
insoluble drug that has attracted great attention in recent years due to its potential anticancer effect in sup-
pressing many types of cancers, while showing a synergistic antitumor effect with other anticancer agents. 
However, curcumin is poorly soluble in aqueous solutions leading to the application of high drug dosage in 
oral formulations. Zeolites, inorganic crystalline aluminosilicates with porous structure on the nano- and 
micro-scale and high internal surface area, can be useful as pharmaceutical carrier systems to encapsulate 
drugs with intrinsic low aqueous solubility and improve their dissolution. Here, we explore the use of zeolite 
type A for encapsulation of curcumin, and we investigate its surface properties and morphology, before 
and after loading of the anticancer agent, using scanning electron microscopy (SEM), powder X-ray diffrac-
tion (XRD), differential scanning calorimetry (DSC), and UV-vis spectroscopy. Results are used to assess the 
loading efficiency of zeolite type A towards curcumin and its structural stability after loading.
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Introduction
The interaction of pharmaceutical molecules with inorganic materials has been receiving considerable atten-
tion in recent years due to the increasing applications of such materials in drug delivery, particularly for tar-
geted treatments of cancer [1, 2]. In cancer therapy, the safe and efficient delivery of chemotherapeutic drugs 
with low permeability and poor solubility in aqueous media is still a challenging task, which can be over-
come through the use of drug-specific delivery systems. According to the World Health Organization (WHO), 
8.2 million deaths in 2012 were linked to cancer, which is well-known as one of the diseases with highest 
mortality worldwide [3].
Conventional cancer treatment with chemotherapy has shown several limitations over the years, includ-
ing insufficient drug concentrations, high cytotoxicity, and problems of multidrug resistance, namely the 
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ability of cancer cells to become simultaneously resistant to different drugs. Drug delivery systems have 
shown a higher efficiency in comparison with traditional drug treatments, but some challenges and limita-
tion still remain. In order to overcome these problems, the development of novel drug delivery systems, such 
as those based on inorganic molecular carriers, would be highly beneficial. Among all the available inorganic 
drug carriers, numerous studies have investigated zeolite structures due to their unique properties, such as 
high adsorption capacity and specific surface area, water solubility, as well as good biocompatibility and 
stability in biological environments [4–6].
Zeolites are inorganic crystalline aluminosilicates with a porous structure on the micro-and nano-
scale and high internal surface area, and they are well known as adsorbents, molecular sieves and ion 
exchange materials in many applications [7, 8]. In the medical and pharmaceutical fields, zeolites have 
recently emerged as promising materials due to their bioactive properties and good stability in biological 
environments [9, 10]. Many zeolites occur in nature as aluminosilicate minerals and more than 200 syn-
thetic zeolites can be prepared in the laboratory [11]. Each zeolite framework has a unique structure, which 
is generally made of silicon, aluminum and oxygen atoms. The building blocks are arranged in a periodic 
way by connections among [SiO4]4− and [AlO4]5− units to form channels and cages, which endow the material 
with its characteristic microporous structure [12, 13]. The pores (α cage) of the zeolites are open, leading to 
the diffusion of molecules from the exterior to the interior of the zeolite particles. The structure of zeolite 
A (Linde type A) is characterized by small pores, as shown in Fig. 1, with each pore defined by an eight-
member oxygen ring, which makes a larger cavity connecting eight sodalite cages on the edges of a cubic 
structure [14].
The unique combination of zeolite properties has resulted into different medical applications of zeo-
lites, for example for the encapsulation and delivery of drugs with anticancer, antibiotics and antimicrobial 
properties [15]. In drug delivery, the zeolitic structures loaded with drugs could be administrated to a patient 
for health treatments, such as cancer therapy, without loss of the individual pharmacological effect of the 
products. In addition, zeolites can bind and encapsulate drugs with low aqueous solubility, thus increasing 
significantly their bioavailability in the physiological environment [16]. Regarding potential toxicity, it has 
been demonstrated that zeolite toxicity strongly depends on the size, shape and composition of the par-
ticles. Micro-sized zeolites characterized by FAU, LTA and LTL structures exhibit low levels of cytotoxicity 
even at high concentrations in cell culture medium. On the other hand, nano-sized zeolites show different 
Fig. 1: Zeolite Linde type A (LTA) framework with the α cage as the unit cell in the middle (black square). Red: oxygen atoms; 
blue: Si/Al atoms [14].
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cytotoxicities, and both alumina component and crystal shape have significant influence on their toxicity 
[17]. For example, pure silica nanozeolite with spherical morphology is nontoxic, but alumina-containing 
nanozeolites ZSM-5, LTL and LTA are toxic. This has been linked to the presence of surface acidic sites, which 
can catalyze chemical reactions of cell membranes and induce the necrosis of cells. In addition, surface 
charge plays an important role on nanoparticle toxicity: positive-charged surfaces are more toxic than neg-
ative-charged ones due to the strong affinity of cationic surface to negatively charged cell membrane [18].
Curcumin, the active ingredient of turmeric (Curcuma longa) plant, is a water-insoluble natural com-
pound that has attracted great attention in recent years in biomedical science. Curcumin is a low-molecular-
weight phenolic compound with a wide range of pharmacological actions and biological activities, including 
anti-cancer [19], anti-microbial, anti-inflammatory, and with low or no intrinsic toxicity for promising clinical 
applications [20, 21]. However, the limited solubility and rapid elimination of curcumin lead to poor bioavail-
ability after oral usage or topical administration [22, 23]. As a consequence, curcumin needs to be applied in 
very high dosage in oral formulations. The use of a zeolite carrier for curcumin has the potential to render the 
drug dispersible and increase its bioavailability.
In our work, we analyse the ability of synthetic zeolite 5A, a Ca2+ exchanged form of zeolite LTA (Fig. 1), 
to load the bioactive compound curcumin, which is well-known for its therapeutic effects. Zeolite 5A has an 
effective pore opening of about 5 Å and Ca2+ ion as a coordinating cation in its structure, leading to a more 
uniform and stable drug delivery system.
The aim of this research was to determine the ability of synthetic zeolites with type A structure for loading 
curcumin by diffusion in liquid phase and adsorption on the surface or in the voids of the zeolite porous 
framework (Fig. 2). The effect of the curcumin concentration on the zeolite loading capacity was studied. The 
structural properties and morphology of the zeolite carrier, before and after curcumin loading, were investi-
gated using scanning electron microscopy (SEM), powder X-ray diffraction (XRD), and differential scanning 
calorimetry (DSC). The encapsulation and adsorption of curcumin on the zeolites surface were analyzed as a 
function of concentration using UV-vis spectroscopy.
Experimental section
Materials and sample preparation
Zeolite 5A, the calcium-exchanged form of zeolite Linde type A, was obtained in bead form from Zeochem AG 
(Switzerland). According to the manufacturer datasheet, this type of zeolite has a nominal pore diameter of 
Fig. 2: Schematic of curcumin adsorption on zeolite surface.
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5 Å. The beads were converted to powder before use by grinding in a ceramic mortar. The final product was 
in powder form with particles below 100 μm in size. Curcumin from Curcuma longa (turmeric) (IUPAC name 
(E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione and common name diferuloylmethane) 
was purchased from Sigma-Aldrich (Schnelldorf, Germany) and used as received. To evaluate the curcumin 
loading capacity, the zeolite powders were first dehydrated in oven at 120 °C overnight to eliminate any water 
inside the pores that would interfere with the adsorption process, and then incubated with the curcumin 
solution for 48 h. For each experiment, 500 mg of zeolite 5A were added to a solution (20 mL) made by dis-
solving curcumin at different concentrations (0.0125, 0.025, 0.05 mol/L) in acetone. The mixtures were stirred 
at room temperature for 48  h. During this time the original white color of the zeolite powder changed to 
yellow, indicating that curcumin was incorporated with the zeolite structure. After curcumin loading, the 
mixtures were filtered and the yellow solid was dried in oven at 50 °C for 12 h to remove residual solvent.
Characterization methods
UV-visible spectroscopy
UV-vis measurements were performed using a Shimadzu UV-2700  spectrophotometer in the range 400–
500 nm (curcumin absorption peak λmax = 419 nm). Curcumin solutions were diluted with pure acetone and 
measured in quartz cells with 1 cm path-length. The zeolite loading capacity was determined by comparing 
the concentration of curcumin in the original incubation solution with the concentration of the superna-
tant after sedimentation of the loaded zeolites. Curcumin concentration in the supernatant was quantified 
through a calibration curve obtained from solutions of known concentration. From the calibration curve, the 
molar extinction coefficient of curcumin in acetone was determined to be 78 297 M−1 cm−1 at 419 nm.
X-ray diffraction (XRD)
X-ray diffraction patterns for the empty and curcumin-loaded zeolites were obtained with a Bruker D8 
ADVANCE diffractometer (Bruker-AXS, Karlsruhe, Germany). All samples were analyzed in powder form. Dif-
fraction data were collected in the 2θ range from 5° to 140° with counting time of 2 s, corresponding to an 
acquisition time of ~3.5 h per pattern. Rietveld refinement analysis of the XRD data was carried out to charac-
terize the crystalline phases in terms of composition and crystallite size.
Scanning electron microscopy (SEM)
SEM analysis was carried out to investigate the microstructure and morphology of the empty and curcumin-
loaded zeolites. In addition, quantitative elemental composition maps of the samples were acquired with an 
energy-dispersive X-ray (EDX) spectrometer. A Zeiss Auriga 405 field-emission microscope (FE-SEM) (Carl 
Zeiss, Oberkochen, Germany) equipped with a Quantax EDX detector (Bruker Nano, NJ, USA) was used for the 
investigation. Zeolite 5A and curcumin-loaded zeolite samples were analyzed without further sample prepa-
ration. Each sample was fixed on steel stub using carbon tape. Samples were analyzed at low accelerating 
voltage (2 kV) and with different magnifications to achieve high-resolution visualization.
Fourier-transform IR spectroscopy
Characterization of the functional groups was carried out with a Spectrum One FTIR spectrometer (Perkin-
Elmer, Waltham, MA, USA) equipped with an attenuated total reflectance (ATR) element (ZnSe crystal). 
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Samples were analyzed at room temperature in the wavenumber range 4000–650 cm−1 by averaging 40 scans 
at a resolution of 4 cm−1. All samples spectra were corrected against the background spectrum of air taken at 
the same instrumental conditions. FTIR spectra were processed using the Perkin-Elmer Spectrum software.
Differential scanning calorimetry (DSC)
The thermal properties of the zeolite samples were studied using a Perkin-Elmer Pyris 1 DSC instrument 
(Perkin-Elmer, Waltham, MA, USA). Samples (~5 mg) were sealed in aluminum pans and measured in the 
temperature range from 25 °C to 300 °C with a heating rate of 10 °C/min under nitrogen flow. Several samples 
(between three and four) were analyzed for each type of empty and curcumin-loaded zeolites to ensure repro-
ducibility of results. An empty aluminum pan was used as the reference cell. Data were corrected by sub-
tracting a baseline measured with an empty pan at the same conditions and were normalized by the sample 
weight. The Perkin-Elmer Thermal Analysis Software provided with the instrument was used for the peak 
analysis.
Results and discussion
In the present study, curcumin, a natural drug known for its anticancer properties, was selected for the inves-
tigation of zeolite 5A structure to act as a drug carrier. In a first set of experiments, the zeolite carrier capacity 
was tested by analyzing the adsorption of curcumin from liquid solutions within the framework of the zeolite. 
This approach was dependent on the diffusion of the drug in an environment that mediated its exposure to 
the zeolite framework.
To determine the loading efficiency (LE%), zeolites were incubated with solutions of different curcumin 
concentration (0.0125, 0.025, 0.05 mol/L in acetone) for 48 h. The maximum concentration of curcumin was 
selected based on the maximum loading capacity obtained for similar zeolites (2:1  mass ratio of drug to 
carrier) previously reported in the literature [24]. After the loading was completed, the supernatant solutions 
with residual drug were separated by sedimentation and analyzed by UV-vis spectroscopy [25, 26]. In the 
UV-vis spectra (Fig. 3), the presence of residual drug was evidenced by the appearance of an intense band 
occurring in the same position of the curcumin band in acetone (λmax = 419 nm). The drug loading efficiency 
Fig. 3: UV-vis spectra of residual curcumin from incubation solutions with different curcumin concentration (mol/L) after 
adsorption on zeolite 5A.
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was determined to be 40 %, 43 % and 51 % for the 0.0125, 0.025 and 0.05 mol/L curcumin incubation solu-
tions, respectively, based on the following formula [27]:
0 sur 0LE% [(C C ) /C ] 100= − ×
where C0 is the concentration of curcumin in the initial incubation solution and Csur is the curcumin con-
centration in the supernatant at the end of the loading procedure. Results from the residual concentration 
analysis showed that the adsorption of curcumin in the zeolite, and so its loading efficiency, increased upon 
increasing the initial concentration of curcumin. This effect has been previously observed for other zeolitic 
frameworks [28], and it is generally explained by the more favorable adsorption of drug molecules on similar 
molecules that are already immobilized on the zeolite surface. In particular, in our study the maximum 
loading efficiency for zeolite 5A was obtained when using 0.05 mol/L of curcumin in the incubation solution.
Preservation of the zeolite 5A structure while acting as drug carrier for curcumin was monitored by 
powder X-ray diffraction (XRD). The XRD patterns of the empty and curcumin-loaded zeolites were recorded 
at 2θ values between 5° and 140° and they are shown in Fig. 4. A Rietveld refinement analysis was carried 
to characterize the crystallite size and phase composition (Table 1). From this analysis, the pristine zeolite 
5A was determined to be of LTA type with small contaminations by other phases (quartz and calcite) prob-
ably formed from the Ca(OH)2 exchange solution [14]. All investigated curcumin-loaded samples exhibited 
XRD patterns similar to that of zeolite 5A. No variation was observed in the characteristic zeolite peaks after 
loading of curcumin, indicating that the framework did not change during the drug loading process. However, 
the XRD Rietveld refinement data showed a decrease of the crystallite size when increasing the concentration 
of the loading drug in the zeolite (Table 1). This result is an indication of the encapsulation of curcumin in 
the zeolite structure, and in particular it can be related to the presence of curcumin in the amorphous and 
disordered phase of the zeolite [29, 30]. In fact, the nominal pore diameter of the zeolite 5A is 5 Å (according 
to the manufacturer Zeochem), which is too small to allow for the free diffusion of curcumin inside the sieve 
Fig. 4: XRD patterns of empty and curcumin-loaded zeolite 5A (incubation in 0.05 mol/L curcumin solution). The data are offset 
for clarity.
Table 1: XRD Rietveld refinement analysis with calculated crystallite size and phase composition for empty and curcumin-
loaded zeolite 5A.
Sample   Zeolite 
type
  a (Å)   Crystallite 
size (nm)
  Microstrain 
ε0
  LTA 
wt%
  Quartz 
wt%
  Calcite 
wt%
Zeolite 5A   LTA   24.6472(2)   92(2)   0.104(3)   97.41(10)   1.16(5)   1.43(9)
Zeolite/curcumin 0.0125 mol/L   LTA   24.6588(2)   78.2(12)   0.094(3)   96.26(8)   1.60(4)   2.14(7)
Zeolite/curcumin 0.05 mol/L   LTA   24.6586(2)   70.7(10)   0.094(3)   97.30(10)   0.78(5)   1.92(9)
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pores. The approximate length of curcumin, as obtained for different conformational isomers by numerical 
modeling [31], is higher than the average zeolite pore size, suggesting that this drug could have some diffi-
culty in diffusing freely inside the zeolite crystalline structure. Furthermore, the density of the silanol groups 
on the zeolite surface has a definite impact on the drug loading, since the curcumin molecules interact with 
surface silanol groups via hydrogen bonding, which promotes curcumin immobilization in the zeolite amor-
phous and disordered phase. Therefore, there might be a large amount of curcumin on the zeolite 5A surface 
rather than inside the nanopores, especially for high concentrations of curcumin in the incubation solution 
(see results by SEM with EDX analysis below). Indeed, the presence of curcumin mainly affects the crystallite 
size, but not the unit cell of the molecular sieve, as indicated by the Rietveld refinement results in Table 1.
The morphology of the zeolite drug carrier before and after loading of curcumin was studied by SEM 
analysis (Fig. 5). No significant changes appear in the zeolite morphology and structure after loading of the 
drug. The SEM images of zeolite 5A and curcumin-loaded zeolite 5A both showed the typical microporous 
crystalline aluminosilicate structure with no specific change in the average particle diameter of the samples 
before and after drug loading. Similar results were obtained in previous works on porous drug carriers, such 
as halloysite-containing microspheres loaded with aspirin and carbonate microparticles loaded with ibupro-
fen or nifedipine [32, 33].
In addition to the imaging, the energy-dispersive X-ray (EDX) analysis was able to detect the presence 
of carbon deriving from the organic curcumin molecule on the surface of the drug loaded zeolite samples 
(Table 2). It is noted that upon increasing the concentration of curcumin in the loading solution the carbon 
content measured on the zeolite surface increases accordingly. This result confirms that the adsorption of 
curcumin on zeolite 5A increases with the molecule concentration in the initial incubation solution, as it was 
determined by UV-vis spectroscopy. Moreover, the ratios of Al, Si and O elements confirmed that there is no 
substantial variation in the composition of the zeolite 5A before and after curcumin loading.
Evidence for the interaction between the curcumin molecules and the zeolite 5A framework was 
researched using Fourier-transform infrared (FTIR) spectroscopy. As reported in Fig. 6, for the pure zeolite 
a b
Fig. 5: SEM images of (a) empty zeolite 5A and (b) curcumin-loaded zeolite (incubation in 0.05 mol/L curcumin solution).
Table 2: Energy-dispersive X-ray analysis of empty and curcumin-loaded zeolite 5A (incubation in solutions with different 
curcumin concentration).
Elements   Zeolite 5A  Zeolite/curcumin 
0.0125 mol/L
  Zeolite/curcumin 
0.025 mol/L
  Zeolite/curcumin 
0.05 mol/L
O   47.42  49.63  48.53  48.57
Si   27.61  21.25  20.28  19.82
Al   11.61  12.88  13.13  12.63
Ca   6.80  10.04  10.87  10.02
C   1.18  1.66  2.43  4.32
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5A sample, characteristic FTIR bands corresponding to the lattice vibrations were observed at wavenumbers 
from 1700 to 800  cm−1. The broad peak at 1013  cm−1 is due to asymmetric stretching vibration of O–Si–O 
groups, whereas the O–H deformation band appears at 1640 cm−1 [34–36]. The FTIR spectrum of curcumin in 
Figs. 6 and 7 shows characteristic bands at 2917, 2849 and 1427 cm−1, which can be attributed to C–H stretching 
and to deformation of methyl groups [37–39]. The two peaks at 1627 and 1502 cm−1 correspond to C=C, C=O, 
and C–C stretching vibration of the benzene ring, whereas the olefinic C–H bending vibration appears at 
1438 cm−1, and the aromatic C–O stretching vibration at 1274 cm−1. The bands at 1025 cm−1 and 963 cm−1 can be 
attributed to C–O stretching and out-of-plane bending of aromatic C–H bonds, respectively [40–42]. For the 
curcumin-loaded zeolite, the FTIR spectrum shows bands in the regions 3000–2800 cm−1 with two specific 
peaks (2917 and 2849 cm−1) that are found in the pure curcumin spectrum and not in that of zeolite 5A. There-
fore, these peaks can be attributed to the presence of drug on the zeolite. The interaction of curcumin with 
the zeolite surface was evidenced by the characteristic curcumin peaks that shifted from 1506 to 1512 cm−1, 
from 1438 to 1442 cm−1 and from 1274 to 1281 cm−1 as a result of intermolecular hydrogen bonding. In addition, 
the curcumin bands at 2917 and 2849 cm−1 became wider in the spectra of the zeolite after loading, which also 
Fig. 6: FTIR spectra of unloaded zeolite 5A, curcumin, and zeolite 5A loaded with curcumin after incubation in 0.05 mol/L 
solution. The spectra are offset for clarity.
Fig. 7: FTIR spectra of unloaded zeolite 5A, curcumin, and curcumin-loaded zeolite 5A (incubation in 0.05 mol/L curcumin 
solution) in the fingerprint region.
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suggests an enhancement of the hydrogen bonding. The zeolite vibrational bands, particularly the main band 
at 1013 cm−1, do not shift or broaden due to curcumin loading, indicating that the zeolite framework remains 
unchanged after loading, as previously found in studies of drug interaction with similar systems [27, 43].
Investigations by differential scanning calorimetry (DSC) of the empty and curcumin-loaded zeolite 5A 
samples were performed in the temperature range 25–300 °C. The empty zeolite 5A shows no significant 
thermal event in the investigated temperature range. On the other hand, the thermograms of pure curcumin 
powder is characterized by the presence of an endothermic peak at 174 °C due to melting, in agreement with 
previously reported data [44]. The DSC data of the curcumin-loaded zeolites showed peaks that are shifted 
with respect to that of pure curcumin, which might be an indication of crystallization of curcumin inside the 
zeolite pores. According to the literature, the effect of drug crystallizing inside the carrier pores can lead to a 
melting point occurring at lower temperatures compared to the melting of the drug outside the pores [45, 46]. 
Indeed, as Fig. 8 shows, there is a shift in the melting point of curcumin, which moves to lower temperatures 
in the loaded samples. In addition, the shape of the melting peak appears different: melting of free curcumin 
(outside the pores) is observed as a sharp peak, while drug melting in the pores gives a broader one. This is 
related to the surface chemistry of the zeolite pores and to the specific interaction of the drug with the pore 
walls. Results from the DSC analysis complement the XRD Rietveld data indicating a possible change in the 
crystallinity of curcumin after incorporation in the zeolite framework. In fact, by increasing the curcumin 
concentration in the initial solution, and so in the zeolite carrier, the interaction of curcumin with the pore 
walls increases leading to a more disordered state of curcumin, which causes a significant reduction of the 
melting peak at higher curcumin concentration (0.05 mol/L) with respect to the lower concentration (0.0125 
and 0.025 mol/L).
Conclusions
Zeolite 5A, the calcium form of zeolite type A, was used to assess its ability for loading the anticancer drug 
curcumin. This zeolite structure was selected because of the numerous and accessible pores, making it a 
favorable candidate for enhanced loading of curcumin. Results from our UV-vis investigation showed that the 
loading efficiency of curcumin in zeolite 5A is increased by increasing the drug concentration of the initial 
incubation solution. This observation was confirmed by DSC and XRD analyses, which showed the presence 
of curcumin inside the zeolite pores and confirmed the stronger interaction of zeolite and curcumin at higher 
loading concentration. The FTIR analysis was able to detect the presence of curcumin in the zeolite structure 
Fig. 8: DSC thermograms of zeolite 5A, curcumin, and curcumin-loaded zeolite 5A after incubation in solutions with different 
concentrations of curcumin. Heating rate: 10 °C/min. Data are offset for clarity.
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and to determine the hydrogen bonding mechanism as the preferential interaction between curcumin and 
the zeolite carrier. Both SEM and XRD studies revealed a stable zeolite structure with preservation of its 
framework integrity after curcumin loading. These results confirmed the presence of curcumin in the zeolite 
5A carrier and support the potential use of this porous material as drug carrier in targeted cancer treatments.
Acknowledgements: The authors would like to thank Mauro Ferrini (Department of Chemical Materials and 
Environmental Engineering, Sapienza University of Rome) for assistance in FTIR spectroscopy. The XRD and 
FE-SEM analyses were performed at the Center for Nanotechnologies Applied to Engineering (CNIS) of Sapi-
enza University.
References
[1] H. Kohay, C. Sarisozen, R. Sawant, A. Jhaveri, V. P. Torchilin, Y. G. Mishael. Acta Biomater. 55, 443 (2017).
[2] Y. M. Lvov, M. M. DeVilliers, R. F. Fakhrullin. Expert Opin. Drug Deliv. 13, 977 (2016).
[3] P. Figueiredo, K. Lintinen, A. Kiriazis, V. Hynninen, Z. Liu, T. Bauleth-Ramos, A. Rahikkala, A. Correia, T. Kohout, B. Sar-
mento, J. Yli-Kauhaluoma, J. Hirvonen, O. Ikkala, M. A. Kostiainen, H. A. Santos. Biomaterials 121, 97 (2017).
[4] P. Abasian, M. Radmansouri, M. Habibi Jouybari, M. V. Ghasemi, A. Mohammadi, M. Irani, F. S. Jazi. Int. J. Biol. Macromol. 
121, 398 (2019).
[5] G. Cerri, M. Farina, A. Brundu, A. Daković, P. Giunchedi, E. Gavini, G. Rassu. Micropor. Mesopor. Mat. 223, 58 (2016).
[6] E. Pérez-Herrero, A. Fernández-Medarde. Eur. J. Pharm. Biopharm. 93, 52 (2015).
[7] V. Ravinayagam, B. Rabindran Jermy. J. Saudi Chem. Soc. (2018).
[8] P. Tavolaro, S. Catalano, G. Martino, A. Tavolaro. Appl. Surf. Sci. 380, 135 (2016).
[9] P. Tavolaro, G. Martino, S. Andò, A. Tavolaro. Mater. Sci. Eng. C 69, 894 (2016).
[10] G. Tegl, V. Stagl, A. Mensah, D. Huber, W. Somitsch, S. Grosse-Kracht, G. M. Guebitz. Eng. Life Sci. 18, 334 (2018).
[11] B. Sadeghalvad, Z. Ahali, A. Azadmehr. Arab. J. Sci. Eng. 41, 2501 (2016).
[12] Y.-P. Guo, T. Long, Z.-F. Song, Z.-A. Zhu. J. Biomed. Mater. Res. B 102, 583 (2013).
[13] E. Khodaverdi, H. A. Soleimani, F. Mohammadpour, F. Hadizadeh. Chem. Biol. Drug Design 87, 849 (2015).
[14] L. Price, K. Leung, A. Sartbaeva. Magnetochemistry 3, 42 (2017).
[15] M. Ghadiri, W. Chrzanowski, R. Rohanizadeh. RSC Adv. 5, 29467 (2015).
[16] C. Karavasili, L. Kokove, I. Kontopoulou, G. K. Eleftheriadis, N. Bouropoulos, D. G. Fatouros. J. Drug Deliv. Sci. Technol. 35, 
91 (2016).
[17] T. Kihara, Y. Zhang, Y. Hu, Q. Mao, Y. Tang, J. Miyake. J. Biosci. Bioeng. 111, 725 (2011).
[18] C. M. Goodman, C. D. McCusker, T. Yilmaz, V. M. Rotello. Bioconjug. Chem. 15, 897 (2004).
[19] M. Salem, S. Rohani, E. R. Gillies. RSC Adv. 4, 10815 (2014).
[20] E. A. M. S. Almeida, I. C. Bellettini, F. P. Garcia, M. T. Farinácio, C. V. Nakamura, A. F. Rubira, A. F. Martins, E. C. Muniz. Car-
bohyd. Poly. 171, 259 (2017).
[21] S. Mangalathillam, N. S. Rejinold, A. Nair, V.-K. Lakshmanan, S. V. Nair, R. Jayakumar. Nanoscale 4, 239 (2012).
[22] S. Gopi, J. Jacob, K. Varma, S. Jude, A. Amalraj, C. A. Arundhathy, R. George, T. R. Sreeraj, C. Divya, A. B. Kunnumakkara, S. 
J. Stohs. Phytother. Res. 31, 1883 (2017).
[23] W. Liu, Y. Zhai, X. Heng, F. Y. Che, W. Chen, D. Sun, G. Zhai. J. Drug Target. 24, 694 (2016).
[24] R. A. Al-Thawabeia, H. A. Hodali. J. Chem. 2015, 9 (2015).
[25] T. Hickey, D. Kreutzer, D. J. Burgess, F. Moussy. Biomaterials 23, 1649 (2002).
[26] X. Yao, X. Niu, K. Ma, P. Huang, J. Grothe, S. Kaskel, Y. Zhu. Small 13, 1602225 (2016).
[27] N. Sanoj Rejinold, M. Muthunarayanan, V. V. Divyarani, P. R. Sreerekha, K. P. Chennazhi, S. V. Nair, H. Tamura, R. Jayakumar. 
J. Colloid Interface Sci. 360, 39 (2011).
[28] T. Sağir, M. Huysal, Z. Durmus, B. Z. Kurt, M. Senel, S. Isık. Biomed. Pharmacother. 77, 182 (2016).
[29] K. Jyoti, M. Baunthiyal, A. Singh. J. Radiat. Res. Appl. Sci. 9, 217 (2016).
[30] F. A. Maulvi, D. H. Lakdawala, A. A. Shaikh, A. R. Desai, H. H. Choksi, R. J. Vaidya, K. M. Ranch, A. R. Koli, B. A. Vyas,  
D. O. Shah. J. Control. Release 226, 47 (2016).
[31] T. M. Kolev, E. A. Velcheva, B. A. Stamboliyska, M. Spiteller. Int. J. Quantum Chem. 102, 1069 (2005).
[32] X. Li, QianYang, J. Ouyang, H. Yang, S. Chang. Appl. Clay Sci. 126, 306 (2016).
[33] D. Preisig, D. Haid, F. J. O. Varum, R. Bravo, R. Alles, J. Huwyler, M. Puchkov. Eur. J.Pharm. Biopharm. 87, 548 (2014).
[34] O. Martinho, N. Vilaça, P. J. G. Castro, R. Amorim, A. M. Fonseca, F. Baltazar, R. M. Reis, I. C. Neves. RSC Adv. 5, 28219 
(2015).
[35] V. Mavrodinova, M. Popova, K. Yoncheva, J. Mihály, Á. Szegedi. J. Colloid Interface Sci. 458, 32 (2015).
Brought to you by | Universita degli Studi di Roma La Sapienza
Authenticated | mariagabriella.santonicola@uniroma1.it author's copy
Download Date | 3/5/20 3:42 PM
Z. Ahali Abadeh et al.: Curcumin-loaded zeolite as anticancer drug carrier      471
[36] X. Wen, F. Yang, Q.-F. Ke, X.-T. Xie, Y.-P. Guo. J. Mater. Chem. B 5, 7866 (2017).
[37] S. Esfandiarpour-Boroujeni, S. Bagheri-Khoulenjani, H. Mirzadeh, S. Amanpour. Carbohyd. Polym. 168, 14 (2017).
[38] L. Miloudi, F. Bonnier, D. Bertrand, H. J. Byrne, X. Perse, I. Chourpa, E. Munnier. Anal. Bioanal. Chem. 409, 4593 (2017).
[39] H. Sandy Budi, H. Lannie, Y. Yanan, M. Anand Kumar, Antaresti, Y. Chengzhong. Nanotechnology 27, 505605 (2016).
[40] R. Adami, A. Di Capua, E. Reverchon. Powder Technol. 305, 455 (2017).
[41] F. Sahne, M. Mohammadi, G. D. Najafpour, A. A. Moghadamnia. Ind. Crops Prod. 95, 686 (2017).
[42] Z. Zhao, M. Xie, Y. Li, A. Chen, G. Li, J. Zhang, H. Hu, X. Wang, S. Li. Int. J. Nanomedicine 10, 3171 (2015).
[43] R. Amorim, N. Vilaça, O. Martinho, R. M. Reis, M. Sardo, J. Rocha, A. M. Fonseca, F. Baltazar, I. C. Neves. J. Phys. Chem. C 
116, 25642 (2012).
[44] S. S. D. Kumar, M. Surianarayanan, R. Vijayaraghavan, A. B. Mandal, D. R. MacFarlane. Eur. J. Pharm. Sci. 51, 34 (2014).
[45] V. Makwana, R. Jain, K. Patel, M. Nivsarkar, A. Joshi. Int. J. Pharm. 495, 439 (2015).
[46] J. Riikonen, E. Mäkilä, J. Salonen, V.-P. Lehto. Langmuir 25, 6137 (2009).
Brought to you by | Universita degli Studi di Roma La Sapienza
Authenticated | mariagabriella.santonicola@uniroma1.it author's copy
Download Date | 3/5/20 3:42 PM
